{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Corlicyte",
            "NStudiesAvail": 430108,
            "NStudiesFound": 1,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 1,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nInclusion Criteria:\n\nMales or non-pregnant, non-lactating females.\nAge 18 or greater at the time of informed consent.\nAble and willing to provide written informed consent.\nType 1 or Type 2 diabetes.\n\nChronic DFU as the index ulcer meeting all of the following criteria:\n\npresent for at least 4 weeks at the time of Screening Visit 1\nlocated below the malleoli of the foot\nextends to the dermis or subcutaneous tissue, surrounded by healthy skin, without evidence of exposed muscle, tendon, bone, or joint capsule\narea measures 1 to 10 cm2 inclusive, at Screening Visit 1, and\nnon-healing (defined as \u226450% reduction in ulcer size by the Baseline Visit, as compared to Screening Visit 1).\nNegative for antibodies to HLA Class I molecules expressed on Corlicyte MSCs, as measured by Luminex HLA single antigen beads, within 3 months prior to start of Treatment Phase without interval sensitizing events.\nFor an index ulcer on the plantar surface of the foot, willingness to offload the foot per study protocol.\nIn women of childbearing potential, willingness to use effective means of birth control during the course of the study; if using systemic birth control, this must have been used for 6 months or longer prior to Screening Visit 1.\n\nExclusion Criteria:\n\nExclusion Criteria:\n\nPlanned DFU treatment to the index ulcer that includes enzymatic agents, cytotoxic agents or any substance(s) that would affect MSC survival during the study period.\nWomen planning to become pregnant during the course of the study.\nSignificant history of, or current evidence of a severe comorbid medical or psychiatric condition such as liver disease, end-stage renal disease, untreated proliferative retinopathy, bleeding diathesis, schizophrenia, or laboratory abnormality that, in the opinion of the Investigator, would preclude enrollment because of unacceptable risk.\nPresence of any skin condition or skin disorder around the index ulcer that might interfere with the diagnosis of or assessment of study-related endpoints, such as atopic dermatitis, eczema, psoriasis, or seborrheic dermatitis.\nPresence of actinic keratosis or skin cancer within 2 cm of the index ulcer.\nCellulitis or other active infection of the index ulcer or any non-index ulcer at Screening.\nUse of an investigational agent for ulcer care within 30 days prior to Screening Visit 1.\nReceipt of an investigational agent or device not approved by the US FDA for marketed use in any indication within 30 days prior to Screening Visit 1.\nPlanned participation in another therapeutic study for any indication prior to completion of study participation.\nUnwillingness or inability to comply with study visits and study procedures for the entire duration of study participation.\nKnown positivity for Human Immunodeficiency Virus (HIV).\nActive osteomyelitis or gangrene of either foot at Screening.\nKnown Methicillin-resistant Staphylococcus aureus (MRSA) infection within 30 days prior to Screening Visit 1.\nPoorly-controlled diabetes mellitus, defined as hemoglobin A1c (HbA1c) >12%.\nUnsuitable for cellular therapy for any reason, in the opinion of the Investigator.\nPlanned use of cell therapy or amniotic membrane treatment for the index ulcer during study participation.\nSignificant titer of antibodies to HLA Class I molecules expressed on Corlicyte MSCs, as measured by Luminex HLA single antigen beads.\nPresence of severe peripheral artery disease (PAD) defined as clinical evidence of critical limb ischemia (CLI) during Screening."
                        ],
                        "EnrollmentCount": [
                              "16"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04104451"
                        ]
                  }
            ]
      }
}